Skin Patch Treats Children’s Peanut Allergies: Two-thirds of children wearing peanut skin patches were safely desensitized to this common kid allergen. #peanut #allergy #patch #desensitization #immunotherapy #viaskin
https://www.instagram.com/drhowardsmithreports/reel/DHWmcgnMxf3/
Howard G. Smith MD, AM on Instagram: "Skin Patch Treats Children’s Peanut Allergies Two-thirds of children wearing peanut skin patches were safely desensitized to this common kid allergen. Pediatric allergists at the University of Colorado followed 298 children 4 to 11 years of age in their phase 3 study of so-called epicutaneous immunotherapy. The Viaskin Peanut Patch delivers 250 ug of peanut protein, and over 90% of the children were able to wear the patch for the entire 5 year study period. The children’s level of tolerance to a stiff peanut protein challenge of 1000 ug rose gradually as they wore the patch. After one year, one-third of the children tolerated this challenge but that figure tripled by the study’s completion. The Viaskin Patch still awaits FDA approval, but it represents a non-invasive, readily tolerated option to the oral route for peanut desensitization. https://www.medscape.com/viewarticle/epicutaneous-immunotherapy-future-peanut-allergy-treatment-2025a10005s3 #peanut #allergy #patch #desensitization #immunotherapy #viaskin"
0 likes, 0 comments - drhowardsmithreports on March 18, 2025: "Skin Patch Treats Children’s Peanut Allergies Two-thirds of children wearing peanut skin patches were safely desensitized to this common kid allergen. Pediatric allergists at the University of Colorado followed 298 children 4 to 11 years of age in their phase 3 study of so-called epicutaneous immunotherapy. The Viaskin Peanut Patch delivers 250 ug of peanut protein, and over 90% of the children were able to wear the patch for the entire 5 year study period. The children’s level of tolerance to a stiff peanut protein challenge of 1000 ug rose gradually as they wore the patch. After one year, one-third of the children tolerated this challenge but that figure tripled by the study’s completion. The Viaskin Patch still awaits FDA approval, but it represents a non-invasive, readily tolerated option to the oral route for peanut desensitization. https://www.medscape.com/viewarticle/epicutaneous-immunotherapy-future-peanut-allergy-treatment-2025a10005s3 #peanut #allergy #patch #desensitization #immunotherapy #viaskin".